Abstract 390P
Background
The intensive incidence rate of oropharyngeal cancer in Uzbekistan has increased over the past 7 years from 1.4 to 2.0 per 100,000 population in 2022, and the proportion of active detection has increased from 25.9 to 32.9%.
Methods
A retrospective analysis of the causes and prevalence of oropharyngeal cancer in the Republic of Uzbekistan was performed. The object of the study were 582 patients from database of RSSPMC of Oncology and Radiology of Uzbekistan who were treated for the period 2020-2022. The study of risk factors was carried out according to gradations: smoking, use of a local variety of tobacco - nasvay, alcohol consumption, a history of trauma, a resident of an urban area, working in gas contamination conditions and dustiness. There were 471 men (80.9%), women - 101 (19.1%). The mean age was 47.3±1.5.
Results
A study of geographical indicators demonstrated that the most common oropharyngeal cancer caused by the use of nasvay occurred in patients from the eastern and southern regions of the republic - 327 (56.2%). In these patients, the average duration of tobacco use was more than 7 years. In contrast, poor climatic conditions caused the development of oral cancer in 89 (15.3%) patients from the Aral Sea region (northwest). The remaining 166 (28.5%) patients were in the central regions of Uzbekistan. When studying risk factors, the vast majority of patients (411 (70.6%)) used nasvay as a bad habit. At the same time, 174 (42.3%) of 411 patients also had smoking and alcohol consumption. Despite the impact of the dusty climate in the Aral Sea zone, 81 (91.0%) patients had a history of alcohol consumption, 19 (21.3%) - smoking. 218 (37.5%) urban residents developed oral cancer due to bad habits (smoking - 174, alcohol - 147, nasvay - 53).
Conclusions
Thus, the analysis of the epidemiological aspects of the development of oral cancer in Uzbekistan indicates that this disease is quite widespread and tends to grow. The main factor is bad habits, in particular the widespread use of nasvay. Only, in the urban population, the influence of nasvay on the development of cancer becomes less, but due to the prevalence of smoking and alcohol abuse, it requires further study to identify specific ways to manage oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tashkent medical academy.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
442P - Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy
Presenter: Yadav Nisha
Session: Poster Display
Resources:
Abstract
443P - Efficacy of vitamin D supplementation in overall survival of cancer patients: Systematic review and meta-analysis
Presenter: Visakha Irawan
Session: Poster Display
Resources:
Abstract
444P - Commencing a nurse led symptom and urgent review clinic (SURC) in a Victorian regional cancer centre
Presenter: Sue Bartlett
Session: Poster Display
Resources:
Abstract
445P - Self-reported symptom burden, quality of life and unmet need of symptom management in nasopharyngeal cancer survivors: A cross-sectional survey
Presenter: Jerry Ching
Session: Poster Display
Resources:
Abstract
446P - A single center experience of anamorelin in patients with non-small cell lung cancer
Presenter: Takanori Ito
Session: Poster Display
Resources:
Abstract
447P - Quality of life in patients with EGFR-mutated lung cancer receiving gefitinib vs gefitinib plus pemetrexed and carboplatin chemotherapy
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
448P - Association of clinicopathological characteristics and pro-inflammatory markers with reduced relative dose intensity in breast cancer chemotherapy
Presenter: Susanna Hutajulu
Session: Poster Display
Resources:
Abstract
449P - Psychometric validation of the MD Anderson symptom inventory head&neck module: Chinese version in nasopharyngeal cancer survivors
Presenter: Victor Tam
Session: Poster Display
Resources:
Abstract
450P - Retrospective study of anamorelin therapy for unresectable or recurrent pancreatic cancer with cancer cachexia
Presenter: Mao Okada
Session: Poster Display
Resources:
Abstract
451P - The real-world efficacy and safety of anamorelin hydrochloride for Japanese unresectable non-small cell lung cancer patients with cachexia
Presenter: Daisuke Arai
Session: Poster Display
Resources:
Abstract